Creation of the Biobank Related to Eye Disease (BioBank)
|ClinicalTrials.gov Identifier: NCT01240343|
Recruitment Status : Completed
First Posted : November 15, 2010
Last Update Posted : January 11, 2018
|Condition or disease|
The purpose of the Biobank related to eye disease at Beaumont Hospital is to help connect specialties and Specialists with each other, outside traditional limits of hospital or laboratory departments. The specimens (blood, fluids, and/or tissue samples) that will be collected from men, women and children will assist the researchers in a variety of studies on human eye diseases.
Research utilizing these specimens will allow for an increased understanding of the etiology, disease process, and response to treatments for various eye diseases, and will provide opportunities to subsequently improve our management decisions. Furthermore, projects that cross over between subspecialties are sparse and that is a limiting factor for the development of research that takes a more comprehensive approach.
|Study Type :||Observational|
|Actual Enrollment :||669 participants|
|Official Title:||Creation of the Biobank Related to Eye Disease|
|Study Start Date :||June 2009|
|Primary Completion Date :||December 4, 2017|
|Study Completion Date :||December 4, 2017|
- To build the platform for a novel application of translational research that links cutting edge molecular laboratory techniques to clinical outcome studiesBiobanks can be used for numberous discovery applications such as: identification and structural characterization of human genes, expression analysis, or discovery proteomics. Biological specimens, when coupled with standardized treatment and outcome data, will be essential resources for the identification, characterization and validation of biomarkers that are predictive of disease and treatment.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01240343
|United States, Michigan|
|William Beaumont Hospital|
|Royal Oak, Michigan, United States, 48073|
|Principal Investigator:||Kimberly Drenser, MD, PhD||Associated Retinal Consultants, P.C.|